Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2014-09-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
NCT02252328
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00006188
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
NCT01138657
Minocycline for Chronic Autoimmune Uveitis
NCT05474729
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01032915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simvastatin and standard treatment
40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
Simvastatin 40mg
standard treatment
conventional treatment of uveitis
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simvastatin 40mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* increased transaminase levels of \>1.5 ULN
* planned or active pregnancy
* use of fibrates, nicotinic acid, cyclosporine A, antifungal drugs, macrolide antibiotics, verapamil, and grapefruit juice (\>1 L/day).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ivan Shirinsky, MD, PhD
Head of the Laboratory of Clinical Immunopharmacology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory of Clinical Immunopharmacology
Novosibirsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shirinsky IV, Biryukova AA, Kalinovskaya NY, Shirinsky VS. Tear cytokines as potential biomarkers in non-infectious uveitis: post hoc analysis of a randomised clinical trial. Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1813-1819. doi: 10.1007/s00417-020-04707-7. Epub 2020 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMV003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.